Expert perspective Yoonhyuk Jang, MD, PhD, Postdoctoral Fellow in the Department of Immunology at Harvard Medical School, commented on the findings: This study suggests that semaglutide may be associated with a lower risk of adult-onset seizures or epilepsy in patients with type 2 diabetes, with the signal appearing more pronounced in late-onset cases among adults aged 60 years or older. He added: Given that age-associated brain insults are major contributors to adult-onset seizures and epilepsy, these findings may have implications beyond seizure risk alone and raise the possibility that semaglutide could also be relevant to broader brain health
Ozempic (semaglutid, ukentlig) primrt for diabetes type 2, kan i enkelte tilfeller vurderes for vektreduksjon
Although causality has not been formally proven, the dermatological community strongly advises against off-label cosmetic use
Although increasingly popular for weight loss, the bone safety profile of semaglutide remained unclear particularly in individuals with different metabolic conditions
Many people worry about getting it wrong, having low blood sugars, gaining weight, or needing more insulin over time